Table 1:
Descriptive characteristics of 23,601 childhood cancer survivors by diagnosis decade and 5,051 siblings
| All survivors | Diagnosis Decade |
Siblings | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1970-1979 | 1980-1989 | 1990-1999 | |||||||||
| N | % | N | % | N | % | N | % | N | % | ||
| Sex | Female | 10947 | 46·4 | 2900 | 46·6 | 4321 | 45·9 | 3726 | 46·8 | 2643 | 52·3 |
| Male | 12654 | 53·6 | 3323 | 53·4 | 5099 | 54·1 | 4232 | 53·2 | 2408 | 47·7 | |
| Race/ethnicity | Non-Hispanic White | 19346 | 82·4 | 5533 | 89·2 | 7796 | 83·1 | 6017 | 76·0 | 4377 | 89·7 |
| Non-Hispanic Black | 1500 | 6·4 | 241 | 3·9 | 577 | 6·2 | 682 | 8·6 | 151 | 3·1 | |
| Hispanic | 1784 | 7·6 | 292 | 4·7 | 616 | 6·6 | 876 | 11·1 | 214 | 4·4 | |
| Other | 862 | 3·7 | 135 | 2·2 | 388 | 4·1 | 339 | 4·3 | 140 | 2·9 | |
| Age at diagnosis | 0-9 years | 14811 | 62·8 | 3830 | 61·5 | 6111 | 64·9 | 4870 | 61·2 | · | · |
| 10-20 years | 8790 | 37·2 | 2393 | 38·5 | 3309 | 35·1 | 3088 | 38·8 | · | · | |
| Age at last follow-up/death | <20 years | 3954 | 16·8 | 402 | 6·5 | 1120 | 11·9 | 2432 | 30·6 | 419 | 8·3 |
| 20-29 years | 9293 | 39·4 | 953 | 15·3 | 4354 | 46·2 | 3986 | 50·1 | 1591 | 31·5 | |
| 30-39 years | 7257 | 30·7 | 2651 | 42·6 | 3088 | 32·8 | 1518 | 19·1 | 1734 | 34·3 | |
| 40-49 years | 2693 | 11·4 | 1816 | 29·2 | 855 | 9·1 | 22 | 0·3 | 1047 | 20·7 | |
| ≥50 years | 404 | 1·7 | 401 | 6·4 | 3 | 0·0 | 0 | 0·0 | 260 | 5·1 | |
| Diagnosis | Acute lymphoblastic leukemia | 6148 | 26·0 | 1824 | 29·3 | 2892 | 30·7 | 1432 | 18·0 | · | · |
| Acute myeloid leukemia | 866 | 3·7 | 131 | 2·1 | 333 | 3·5 | 402 | 5·1 | · | · | |
| Other leukemia1 | 303 | 1·3 | 74 | 1·2 | 105 | 1·1 | 124 | 1·6 | · | · | |
| Astrocytomas | 2594 | 11·0 | 509 | 8·2 | 945 | 10·0 | 1140 | 14·3 | · | · | |
| Medulloblastoma, PNET | 997 | 4·2 | 148 | 2·4 | 349 | 3·7 | 500 | 6·3 | · | · | |
| Other CNS tumors2 | 645 | 2·7 | 79 | 1·3 | 206 | 2·2 | 360 | 4·5 | · | · | |
| Hodgkin lymphoma | 2996 | 12·7 | 1097 | 17·6 | 1057 | 11·2 | 842 | 10·6 | · | · | |
| Non-Hodgkin lymphoma | 1932 | 8·2 | 453 | 7·3 | 774 | 8·2 | 705 | 8·9 | · | · | |
| Wilms tumor | 2148 | 9·1 | 534 | 8·6 | 877 | 9·3 | 737 | 9·3 | · | · | |
| Neuroblastoma | 1838 | 7·8 | 443 | 7·1 | 674 | 7·2 | 721 | 9·1 | · | · | |
| Soft tissue sarcoma | 1162 | 4·9 | 365 | 5·9 | 448 | 4·8 | 349 | 4·4 | · | · | |
| Ewing sarcoma | 714 | 3·0 | 203 | 3·3 | 277 | 2·9 | 234 | 2·9 | · | · | |
| Osteosarcoma | 1205 | 5·1 | 360 | 5·8 | 474 | 5·0 | 371 | 4·7 | · | · | |
| Other bone tumors3 | 53 | 0·2 | 3 | 0·0 | 9 | 0·1 | 41 | 0·5 | · | · | |
| Radiation | None | 9275 | 43·1 | 1219 | 22·6 | 3588 | 42·5 | 4468 | 58·1 | · | · |
| Any site | 12245 | 56·9 | 4163 | 77·4 | 4855 | 57·5 | 3227 | 41·9 | · | · | |
| Chest | 5393 | 25·4 | 1737 | 33·2 | 1975 | 23·8 | 1681 | 21·9 | · | · | |
| Brain/spine | 6497 | 30·6 | 2030 | 38·8 | 2734 | 33·0 | 1733 | 22·5 | · | · | |
| Abdomen | 5112 | 24·1 | 1723 | 32·9 | 1837 | 22·2 | 1552 | 20·2 | · | · | |
| Pelvis | 4234 | 20·0 | 1390 | 26·5 | 1527 | 18·4 | 1317 | 17·1 | · | · | |
| Alkylating agents | None | 9747 | 48·7 | 2793 | 58·5 | 3663 | 46·4 | 3291 | 44·7 | · | · |
| (cyclophosphamide equivalent dose) | Any | 10287 | 51·3 | 1978 | 41·5 | 4236 | 53·6 | 4073 | 55·3 | · | · |
| 1<4000 mg/m2 | 2563 | 12·8 | 341 | 7·1 | 1193 | 15·1 | 1029 | 14·0 | · | · | |
| 4000-<8000 mg/m2 | 2641 | 13·2 | 406 | 8·5 | 1045 | 13·2 | 1190 | 16·2 | · | · | |
| 8000-<12000 mg/m2 | 2093 | 10·4 | 396 | 8·3 | 886 | 11·2 | 811 | 11·0 | · | · | |
| 12000-<16000 mg/m2 | 1191 | 5·9 | 301 | 6·3 | 545 | 6·9 | 345 | 4·7 | · | · | |
| 16000-<20000 mg/m2 | 684 | 3·4 | 207 | 4·3 | 284 | 3·6 | 193 | 2·6 | · | · | |
| ≥20000 mg/m2 | 1115 | 5·6 | 327 | 6·9 | 283 | 3·6 | 505 | 6·9 | · | · | |
| Anthracyclines (doxorubicin equivalent dose) | None | 11198 | 53·6 | 3721 | 72·0 | 4262 | 52·2 | 3215 | 42·6 | · | · |
| Any | 9676 | 46·4 | 1445 | 28·0 | 3904 | 47·8 | 4327 | 57·4 | · | · | |
| 1<100 mg/m2 | 1395 | 6·7 | 118 | 2·3 | 552 | 6·8 | 725 | 9·6 | · | · | |
| 100-<250 mg/m2 | 4013 | 19·2 | 354 | 6·9 | 1366 | 16·7 | 2293 | 30·4 | · | · | |
| 250-<400 mg/m2 | 2889 | 13·8 | 490 | 9·5 | 1404 | 17·2 | 995 | 13·2 | · | · | |
| ≥400 mg/m2 | 1379 | 6·6 | 483 | 9·3 | 582 | 7·1 | 314 | 4·2 | · | · | |
| Epipodophyllotoxins | None | 17579 | 82·9 | 5251 | 97·9 | 7174 | 86·3 | 5154 | 68·5 | · | · |
| Any | 3618 | 17·1 | 115 | 2·1 | 1137 | 13·7 | 2366 | 31·5 | · | · | |
| 1<100 mg/m2 | 31 | 0·1 | · | · | 7 | 0·1 | 24 | 0·3 | · | · | |
| ≥100 mg/m2 | 3587 | 16·9 | 115 | 2·1 | 1130 | 13·6 | 2342 | 31·1 | · | · | |
| Platinums | None | 19080 | 89·3 | 5332 | 98·9 | 7608 | 90·6 | 6140 | 81·0 | · | · |
| Any | 2289 | 10·7 | 58 | 1·1 | 787 | 9·4 | 1444 | 19·0 | |||
| 1<300 mg/m2 | 466 | 2·2 | 17 | 0·3 | 176 | 2·1 | 273 | 3·6 | · | · | |
| ≥300 mg/m2 | 1823 | 8·5 | 41 | 0·8 | 611 | 7·3 | 1171 | 15·4 | · | · | |
Note: % reported among non-missing; # with unknown values: n=278 race, n=1909 survivors did not provide consent for release of medical records (Supplemental Table S2); additionally missing: n=172 radiation, 483 chest RT,476 CNS RT,483 abdomen RT,482 pelvis RT, 1658 CED dose, 818 anthracycline dose, 495 epipodophyllotoxin dose, 219 bleomycin dose, 323 platinum dose.
Other leukemias (with more than 3 cases): leukemia, NOS (n=40); acute leukemia, NOS (n=59); prolymphocytic leukemia, NOS (n=16); adult T-cell leukemia/lymphoma, HTLV-1 positive (n=17); sub-acute myeloid leukemia (n=18); chronic myeloid leukemia, NOS (n=124); chronic myelomonocytic leukemia, NOS (n=4); myelodysplastic syndrome, NOS (n=8)
Other CNS tumors (with more than 3 cases): pineoblastoma (n=21); subependymal giant cell astrocytoma (n=23); choroid plexus carcinoma (n=27); ependymoma, NOS (n=331); ependymoma, anaplastic (n=34); papillary ependymoma (n=5); myxopapillary ependymoma (n=16); oligodendroglioma, NOS (n=107); oligodendroglioma, anaplastic (n=5); ganglioglioma, NOS (n=75)
Other bone tumors (with more than 3 cases): peripheral neuroectodermal tumor (n=52)